Leading Companies

Global Radial Compression Device Market: Key Developments

In May 2021, the study result presented at U.S. in the Society for Cardiovascular Angiography and Interventions (SCAI) 2021 Scientific Sessions, stated that he adjunctive use of the hemostatic patch safely facilitates early deflation of the TR Band after transradial procedures without any of the complications associated with longer or more-aggressive compression,such as radial artery occlusion and hematomas. The patch is composed of a hydrophilic polymer that dehydrates blood and potassium ferrate that clumps the blood solids and proteins together to form a seal at the surface of the skin.

On 26 April 2023, Terumo Europe N.V., a medical device company, announced the start of a new prospective clinical study: the Ultimaster Nagomi sirolimus eluting coronary stent system in complex PCI patients. Ultimaster Nagomi helps in mastering rapid coronary vascular repair in CVD patients.

In September 2022, at the Transcatheter Cardiovascular Therapeutics (TCT2022) conference, the Cardiovascular Research Foundation's (CRF) annual scientific symposium, and one of the world's premier educational forums specializing in interventional cardiovascular medicine, GE Healthcare presents innovations created to shape the cardiology care of the future.

Global Radial Compression Device Market: Key Trends

Better Healthcare Infrastructure, Effective government policies

Due to improved healthcare infrastructure, effective government policies, a sizable base of multinational corporations, and rising genetic illnesses, the radial compression device market is expected to witness considerable expansion in the North American region. According to the article released in May 2021, for radial access procedures, novel hemostasis strategies have been disclosed, notably the Prelude SYNC DISTAL (PSD) radial compression device from Merit Medical Systems, Inc., South Jordan, Utah, and USA. This study aimed to compare the safety profiles of PSD and Terumo radial (TR) Band.